Clinical Cancer Research Grants Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Labriolle-Vaylet, C.
Right arrow Articles by Gruaz-Guyon, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Labriolle-Vaylet, C.
Right arrow Articles by Gruaz-Guyon, A.
Clinical Cancer Research Vol. 6, 363-371, February 2000
© 2000 American Association for Cancer Research


Clinical Trials

Successful Surgical Removal of Occult Metastases of Medullary Thyroid Carcinoma Recurrences with the Help of Immunoscintigraphy and Radioimmunoguided Surgery1

Claire de Labriolle-Vaylet, Pierre Cattan, Emile Sarfati, Michel Wioland, Claire Billotey, Claude Brochériou, Eric Rouvier, Anne de Roquancourt, William Rostène, Serge Askienazy, Jacques Barbet, Gérard Milhaud and Anne Gruaz-Guyon2

Institut National de la Santé et de la Recherche Médicale U.339 [C. d. L-V., W. R., A. G-G.], Service de Médecine Nucléaire [C. d. L-V., S. A.], and Faculté de Médecine [G. M.], Hôpital Saint-Antoine, 75012 Paris; Service de Chirurgie [P. C., E. S.], Service de Médecine Nucléaire [C. B.], and Service d’Anatomopathologie [C. B., A. d. R.], Hôpital Saint-Louis, Paris; Service de Médecine Nucléaire, Hôpital Trousseau, Paris [M. W.]; and Immunotech SA, Marseille [E. R., J. B.], France

Patients with recurrent or metastatic medullary thyroid carcinoma (MTC) were referred for pretargeted immunoscintigraphy (Affinity Enhancement System; AES) and radioimmunoguided surgery (RIGS). Data collected from 13 patients establish that whole-body AES immunoscintigraphy revealed metastases <360 mg and RIGS detected micrometastases (5–15 mg). All tissue samples removed by the surgeon were diagnosed by histology and immunohistochemistry of calcitonin to check the accuracy of IS and RIGS results. AES immunoscintigraphy is very sensitive. Of 34 metastases or recurrences detected, 22 had escaped physical examination or conventional imaging. The accuracy of RIGS was 86%, its sensitivity 75%, and its specificity was 90% (n = 208). IS and RIGS detected occult tumors that would have escaped surgery, clearly demonstrating clinical benefit. Serum calcitonin (normal, 10 pg/ml) and carcinoembryonic antigen (normal, 5 ng/ml) of two patients were restored to normal. In patients whose tumors were discovered, progression of their disease was slowed, as evidenced by the large decrease in serum calcitonin and carcinoembryonic antigen, an important prognostic factor. Surgery was canceled in one case where IS detected distant metastases out of surgical reach. Thus, AES immunoscintigraphy and RIGS might be of valuable help for the surgical management of medullary thyroid carcinoma.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
A. Sezeur, F.P. Chatelet, Ch. Cywiner, Cl. de Labriolle-Vaylet, C. Chastang, Cl. Billotey, M. Malafosse, D. Gallot, P. Betton, F. Montravers, et al.
Pathology Underrates Colon Cancer Extranodal and Nodal Metastases; Ex vivo Radioimmunodetection Helps Staging
Clin. Cancer Res., September 15, 2007; 13(18): 5592s - 5597s.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. Stein and D. M. Goldenberg
A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy
Mol. Cancer Ther., December 1, 2004; 3(12): 1559 - 1564.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Gutowski, M. Carcenac, D. Pourquier, C. Larroque, B. Saint-Aubert, P. Rouanet, and A. Pèlegrin
Intraoperative Immunophotodetection for Radical Resection of Cancers: Evaluation in an Experimental Model
Clin. Cancer Res., May 1, 2001; 7(5): 1142 - 1148.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.